

AssayMax™ Human Lp(a) ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μl of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 25 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key

Consult instructions for use.

Assay Template

| 12 | | | | | | | | |
|----|---|---|---|---|---|---|---|---|
| 11 | | | | | | | | |
| 10 | | | | | | | | |
| 6 | | | | | | | | |
| ∞ | | | | | | | | |
| 7 | | | | | | | | |
| 9 | | | | | | | | |
| ß | | | | | | | | |
| 4 | | | | | | | | |
| æ | | | | | | | | |
| 2 | | | | | | | | |
| 1 | | | | | | | | |
| | A | B | С | D | Е | Ŀ | Ð | т |

AssayMax[™] Human Lipoprotein(a) [Lp(a)] ELISA Kit

Catalog No. EL3001-1 Sample insert for reference use only

Introduction

Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein particle formed by an assembly of LDL particles and Apo(a) bound to Apo-B100 component of LDL (1). Apo(a), the main constituent of Lp(a), has serine proteinase activity and is capable of autoproteolysis (2). Apo(a) has 4548 amino acids, variable sizes from 200 – 700 kDa, multiple isoforms, and structural homology with plasminogen (3-5). It competes with plasminogen for its binding site, inhibiting tissue-type plasminogen activator 1 and leading to reduced fibrinolysis (6). The mean Lp(a) protein level ranges from 78 – 175 μ g/ml depending on populations and the risk threshold is 300 μ g/ml (7-9). High levels of Lp(a) in the blood is a risk factor for myocardial infarction (MI), coronary heart disease (CHD), cerebrovascular disease (CVD), atherosclerosis, thrombosis, and stroke (10-11).

Principle of the Assay

The AssayMax[™] Human Lp(a) ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of Lp(a) in human **plasma, serum, milk, urine, and CSF samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures human Lp(a) in approximately 4 hours. A polyclonal antibody specific for human Lp(a) has been pre-coated onto a 96-well microplate with removable strips. Lp(a) in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human Lp(a), which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for **Research Use Only** and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Lp(a) Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human Lp(a).
- **Sealing Tapes:** Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Lp(a) Standard: Human Lp(a) in a buffered protein base (15 ng, lyophilized, 2 vials).
- **Biotinylated Human Lp(a) Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human Lp(a) [120 μ].
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 µl).
- **Chromogen Substrate (1x):** A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

Microplate reader capable of measuring absorbance at 450 nm

- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. An 8000-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. An 8000-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. A 4000-fold sample dilution is suggested into EIA Diluent or within the range of 400x – 10000x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Urine: Collect urine using sample pot. Centrifuge samples at 800 x g for 10 minutes. A 4-fold sample dilution is suggested into EIA Diluent or within the range of 1x – 20x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **CSF:** Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent or within the range of 1x 20x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

| | Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested) | | | |
|----|--|--------|---|--|
| | 100x | IIISEI | 10000x | |
| | | | | |
| A) | 4 μl sample : 396 μl buffer (100x) | A) | 4 μl sample : 396 μl buffer (100x) | |
| | = 100-fold dilution | B) | 4 μl of A : 396 μl buffer (100x) | |
| | | | = 10000-fold dilution | |
| | Assuming the needed volume is less than | | Assuming the needed volume is less than | |
| | or equal to 400 μl. | | or equal to 400 μl. | |
| | 1000x | | 100000x | |
| | | | | |
| A) | 4 μl sample : 396 μl buffer (100x) | A) | 4 μl sample : 396 μl buffer (100x) | |
| B) | 24 μl of A : 216 μl buffer (10x) | B) | 4 μl of A : 396 μl buffer (100x) | |
| | = 1000-fold dilution | C) | 24 μl of B : 216 μl buffer (10x) | |
| | | | = 100000-fold dilution | |
| | Assuming the needed volume is less than | | Assuming the needed volume is less than | |
| | or equal to 240 μl. | | or equal to 240 μl. | |

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Lp(a) Standard: Reconstitute the Human Lp(a) Standard (15 ng) with 0.3 ml of EIA Diluent to generate a 50 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (50 ng/ml) 2-fold with equal volume of EIA Diluent to produce 25, 12.5, 6.25, 3.125, and 1.563 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 30 days.

| Standard Point | Dilution | [Lp(a)] (ng/ml) |
|-------------------|--------------------------------|--------------------|
| P1 | 1 part Standard (50 ng/ml) | 50 |
| P2 | 1 part P1 + 1 part EIA Diluent | 25 |
| P3 | 1 part P2 + 1 part EIA Diluent | 12.5 |
| P4 | 1 part P3 + 1 part EIA Diluent | 6.25 |
| P5 | 1 part P4 + 1 part EIA Diluent | 3.125 |
| P6 | 1 part P5 + 1 part EIA Diluent | 1.563 |
| P7 | EIA Diluent | 0.0 |

- Biotinylated Human Lp(a) Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved.
- **SP Conjugate (100x):** Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with EIA Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μ l of Human Lp(a) Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Lp(a) Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 μl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed.

Incubate in ambient light for 25 minutes or until the optimal blue color density develops.

- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

| Standard Point | ng/ml | OD | Average OD |
|----------------|----------------|-------|------------|
| P1 | 50 | 2.437 | 2.398 |
| PI | 50 | 2.359 | 2.390 |
| P2 | 25 | 1.619 | 1.662 |
| FΖ | 25 | 1.705 | 1.002 |
| Р3 | 12.5 | 0.947 | 0.921 |
| гэ | 12.5 | 0.895 | 0.921 |
| P4 | 6.25 | 0.497 | 0.514 |
| F 4 | 0.25 | 0.531 | 0.514 |
| P5 | 3.125 | 0.289 | 0.281 |
| FJ | 5.125 | 0.273 | 0.201 |
| P6 | 1.563 | 0.179 | 0.174 |
| 10 | 1.505 | 0.169 | 0.174 |
| Р7 | 0.0 | 0.056 | 0.054 |
| 17 | 0.0 | 0.052 | 0.054 |
| Sample: Po | oled Normal | 0.886 | 0.004 |
| Sodium Citrate | Plasma (8000x) | 0.922 | 0.904 |
| Sample: Poo | oled Normal | 1.108 | 1 1 2 5 |
| Serum | (8000x) | 1.162 | 1.135 |

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.





Reference Value

- Normal human Lp(a) plasma and serum levels range from 70 180 μg/ml.
- Plasma and serum samples from healthy adults were tested (n=20). On average, human Lp(a) level was 108 μg/ml.

| Sample | n | Average Value (µg/ml) |
|----------------------|----|-----------------------|
| Pooled Normal Plasma | 10 | 95 |
| Pooled Normal Serum | 10 | 120 |

Performance Characteristics

- The minimum detectable dose of human Lp(a) as calculated by 2SD from the mean of a zero standard was established to be 0.49 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

| | Intra-Assay Precision | | | Inter-Assay Precision | | |
|-------------------|-----------------------|------|------|-----------------------|------|-------|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| CV (%) | 3.2% | 4.3% | 5.4% | 8.6% | 9.9% | 10.7% |
| Average CV (%) | 4.3% | | | | 9.7% | |

Spiking Recovery

• Recovery was determined by spiking two plasma samples with different Lp(a) concentrations.

| Sample | Unspiked Sample (ng/ml) | Spiking Value (ng/ml) | Expected | Observed | Recovery (%) |
|----------------------|-------------------------------|-----------------------------|----------|----------|-----------------|
| | 7.5 | 2.0 | 9.5 | 9.3 | 98% |
| 1 | | 7.5 | 15.0 | 13.7 | 91% |
| | | 15.0 | 22.5 | 23.0 | 102% |
| | 15.8 | 2.0 | 17.8 | 19.1 | 107% |
| 2 | | 7.5 | 23.3 | 24.7 | 106% |
| | | 15.0 | 30.8 | 32.4 | 105% |
| Average Recovery (%) | | | | | 102% |

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

| Average Percentage of Expected Value (%) | | | | |
|--|--------|-------|--|--|
| Sample Dilution | Plasma | Serum | | |
| 4000x | 90% | 90% | | |
| 8000x | 100% | 98% | | |
| 16000x | 107% | 109% | | |

Cross-Reactivity

| Species | Cross-Reactivity (%) |
|-------------|----------------------|
| Canine | None |
| Bovine | None |
| Equine | None |
| Monkey | <10% |
| Mouse | None |
| Rat | None |
| Swine | None |
| Rabbit | None |
| Protein | Cross-Reactivity (%) |
| Аро В | 10% |
| HDL | 2% |
| LDL | 6% |
| Plasminogen | 2% |

• No significant cross-reactivity observed with Apo A1, Apo A2, Apo A4, Apo A5, Apo C1, Apo C2, Apo C3, Apo E, Apo H, and Apo M.

Troubleshooting

| Issue | Causes | Course of Action |
|-----------|--|---|
| | Use of improper components | Check the expiration date listed before use. Do not interchange components from different lots. |
| Precision | Improper wash step | Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique. |
| Low | Splashing of reagents while loading wells | Pipette properly in a controlled and careful manner. |
| | Inconsistent volumes loaded into wells | Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance. |

| | | Thoroughly agitate the lyophilized components after |
|--|--------------------------------|---|
| | Insufficient mixing of | reconstitution. |
| | reagent dilutions | Thoroughly mix dilutions. |
| | | Check the microplate pouch for proper sealing. |
| | Improperly sealed | Check that the microplate pouch has no punctures. |
| | microplate | Check that three desiccants are inside the microplate |
| | | pouch prior to sealing. |
| | Microplate was left | Each step of the procedure should be performed |
| lar | unattended between | uninterrupted. |
| igi | steps | |
| h S | Omission of step | Consult the provided procedure for complete list of steps. |
| ligl | Steps performed in | Consult the provided procedure for the correct order. |
| L L | incorrect order | |
| it, o | Insufficient amount of | Check pipette calibration. |
| NO | reagents added to wells | Check pipette for proper performance. |
| Unexpectedly Low or High Signal Intensity | Wash step was skipped | Consult the provided procedure for all wash steps. |
| edl | Improper wash buffer | Check that the correct wash buffer is being used. |
| ç | Improper reagent | Consult reagent preparation section for the correct |
| çpe | preparation | dilutions of all reagents. |
|)e | Insufficient or | Consult the provided procedure for correct incubation |
| 5 | prolonged incubation | time. |
| | periods | |
| | | Sandwich ELISA: If samples generate OD values higher |
| | | than the highest standard point (P1), dilute samples |
| <u>ц</u> | New entired seconds | further and repeat the assay. |
| Ξ | Non-optimal sample dilution | Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples |
| ve. | unution | further and repeat the assay. |
| n n | | User should determine the optimal dilution factor for |
| 0 p | | samples. |
| Deficient Standard Curve Fit | Contamination of | A new tip must be used for each addition of different |
| u n | reagents | samples or reagents during the assay procedure. |
| Sta | Contents of wells | Verify that the sealing film is firmly in place before placing |
| t | evaporate | the assay in the incubator or at room temperature. |
| ie | | Pipette properly in a controlled and careful manner. |
| fic | Improper pipetting | Check pipette calibration. |
| ŏ | | Check pipette for proper performance. |
| | Insufficient mixing of | Thoroughly agitate the lyophilized components after |
| | reagent dilutions | reconstitution. |
| | . cuperir unutions | Thoroughly mix dilutions. |

References

- (1) Wild SH et al. (1997) Arteriosclerosis, Thrombosis, and Vascular Biology. 17:239-245.
- (2) Salonen EM et al. (1989) EMBO J. 8:4035-4040.
- (3) Gaubatz JW et al. (1983) J Biol Chem. 258:4582-4589.
- (4) Eaton DL et al. (1987) Proc Natl Acad Sci USA. 84:3224.
- (5) McLean JW et al. (1987) Nature. 330:132.
- (6) Hajjar KA et al. (1989) Nature. 339:303-305.
- (7) Utermann G. (1989) Science. 246:904-910.
- (8) Schreiner PJ et al. (1993) Arterioscler Thromb Vasc Biol. 13:826-833.
- (9) Marcovina SM et al. (2000) Clin Chem. 46:1956-1967.
- (10) Rhoads GG et al. (1986) JAMA. 256:2540-2544.
- (11) Hoefler G et al. (1988) Arteriosclerosis. 8:398-401.

Version 4.1